Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China; ; China Liver Transplant Registry, Shenzhen 518054, China.
China Liver Transplant Registry, Shenzhen 518054, China.
Hepatobiliary Surg Nutr. 2013 Aug;2(4):188-97. doi: 10.3978/j.issn.2304-3881.2013.08.09.
China Liver Transplant Registry (CLTR) is the official national liver transplant registry in Mainland China that has been authorized by the National Health and Family Planning Commission of the People's Republic of China (NHFPC) and serves for both regulatory and scientific purposes. The CLTR 2011 annual scientific reports released national statistics describing current status of liver transplant (LT) in China. This article, as an accompanying document of CLTR 2011 annual scientific report, provides an overview of scientific results for LT in China. Up to December 2011, a total number of 20,877 LT performed during 1980-2011 in 81 certified transplant centers had been reported to CLTR. Of these donated livers, 92.63% were procured from deceased donors (N=19,338) and 7.37% were from living donors (N=1,539). In March 2010, the pilot project of the new deceased organ donation was initiated. From the initiation of the pilot program to the end of 2011, there were 115 LT (0.55% of all LT) using the liver grafts from Chinese categories donors. The recipient post-transplant survival had been significantly improved over years. The median post-transplant follow-up was 14.74 months, of which the longest follow-up time was 192.47 months. The 1-year, 3-year and 5-year cumulative survival rate for all recipients was 77.97%, 65.38% and 60.53%, respectively.
中国肝移植注册中心(CLTR)是中国大陆官方的国家肝移植注册中心,由中华人民共和国国家卫生和计划生育委员会(NHFPC)授权,兼具监管和科研目的。CLTR 2011 年年度科学报告发布了全国性的肝移植(LT)统计数据,描述了中国当前的肝移植状况。本文作为 CLTR 2011 年年度科学报告的配套文件,概述了中国肝移植的科学研究成果。截至 2011 年 12 月,81 个经认证的移植中心共报告了 1980 年至 2011 年期间进行的 20877 例 LT。这些供体肝脏中,92.63%(N=19338)来自于已故供体,7.37%(N=1539)来自于活体供体。2010 年 3 月,启动了新的已故器官捐献试点项目。从试点项目启动到 2011 年底,共有 115 例 LT(所有 LT 的 0.55%)使用了来自中国类别的供体的肝脏移植物。受者的移植后存活率多年来显著提高。中位移植后随访时间为 14.74 个月,最长随访时间为 192.47 个月。所有受者的 1 年、3 年和 5 年累积生存率分别为 77.97%、65.38%和 60.53%。